Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

CENTRAL WASHINGTON SLEEP DIAGNOSTIC CENTER, PLLC

NPI: 1629265798 · WENATCHEE, WA 98801 · Addiction Medicine (Family Medicine) Physician · NPI assigned 10/02/2007

$2.30M
Total Medicaid Paid
37,036
Total Claims
26,566
Beneficiaries
27
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialHAEGER, ERIC (CEO)
NPI Enumeration Date10/02/2007

Related Entities

Other providers sharing the same authorized official: HAEGER, ERIC

ProviderCityStateTotal Paid
CENTRAL WASHINGTON SLEEP DIAGNOSTIC CENTER, PLLC MOSES LAKE WA $6.90M
CENTRAL WASHINGTON SLEEP DIAGNOSTIC CENTER, PLLC BREWSTER WA $1.23M

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 12,338 $680K
2019 8,127 $569K
2020 5,025 $292K
2021 3,898 $253K
2022 2,935 $182K
2023 2,992 $223K
2024 1,721 $105K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 16,403 10,614 $1.26M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 5,401 3,107 $319K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 1,109 937 $147K
E0601 Continuous positive airway pressure (cpap) device 729 719 $136K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 474 346 $61K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 505 494 $53K
A7038 Filter, disposable, used with positive airway pressure device 3,763 3,677 $36K
95811 87 87 $34K
99205 Prolong outpt/office vis 269 267 $30K
A4604 Tubing with integrated heating element for use with positive airway pressure device 513 481 $30K
A7034 Nasal interface (mask or cannula type) used with positive airway pressure device, with or without head strap 294 289 $29K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 183 155 $25K
A7035 Headgear used with positive airway pressure device 663 631 $24K
Q3014 Telehealth originating site facility fee 1,002 786 $22K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 318 292 $17K
84703 1,987 1,098 $15K
80305 1,320 668 $15K
99354 181 178 $13K
A7032 Cushion for use on nasal mask interface, replacement only, each 223 213 $9K
E0562 Humidifier, heated, used with positive airway pressure device 27 27 $8K
A7039 Filter, non disposable, used with positive airway pressure device 510 479 $7K
A7046 Water chamber for humidifier, used with positive airway pressure device, replacement, each 581 549 $7K
95810 Polysomnography; sleep staging with 4 or more additional parameters 15 15 $5K
A7036 Chinstrap used with positive airway pressure device 122 120 $2K
A7033 Pillow for use on nasal cannula type interface, replacement only, pair 16 16 $577.06
99457 190 174 $144.67
99091 151 147 $0.00